Literature DB >> 25921386

Role of Microenvironment in Resistance to Therapy in AML.

Yoko Tabe1, Marina Konopleva.   

Abstract

As part of the dynamic interactions between leukemic cells and cells of the bone marrow microenvironment, specific niches provide a sanctuary where subpopulations of leukemic cells evade chemotherapy-induced death and acquire a drug-resistant phenotype. This review focuses on the cellular and molecular biology of the leukemia stem cell (LSC) niche and of microenvironment/leukemia interactions. Key emerging therapeutic targets include chemokine receptors, adhesion molecules, the sympathetic nervous system, and hypoxia-related proteins, as well as the genetic and epigenetic abnormalities of the leukemia-associated stroma. The complex interplay between LSCs and microenvironment components provides a rationale for appropriately tailored molecular therapies designed to improve outcomes in leukemia. Further understanding of the contribution of the bone marrow niche to the process of leukemogenesis may provide new targets that allow destruction of LSCs without adversely affecting normal stem cell self-renewal.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25921386      PMCID: PMC4447522          DOI: 10.1007/s11899-015-0253-6

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  69 in total

1.  Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow.

Authors:  Yoshio Katayama; Michela Battista; Wei-Ming Kao; Andrés Hidalgo; Anna J Peired; Steven A Thomas; Paul S Frenette
Journal:  Cell       Date:  2006-01-27       Impact factor: 41.582

Review 2.  The vascular niche: home for normal and malignant hematopoietic stem cells.

Authors:  P L Doan; J P Chute
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528

Review 3.  Stromal abnormalities in neoplastic bone marrow diseases.

Authors:  U Dührsen; D K Hossfeld
Journal:  Ann Hematol       Date:  1996-08       Impact factor: 3.673

4.  Targeting of CD44 eradicates human acute myeloid leukemic stem cells.

Authors:  Liqing Jin; Kristin J Hope; Qiongli Zhai; Florence Smadja-Joffe; John E Dick
Journal:  Nat Med       Date:  2006-09-24       Impact factor: 53.440

5.  LRRK2 functions in synaptic vesicle endocytosis through a kinase-dependent mechanism.

Authors:  Amaia M Arranz; Lore Delbroek; Kristof Van Kolen; Marco R Guimarães; Wim Mandemakers; Guy Daneels; Samer Matta; Sara Calafate; Hamdy Shaban; Pieter Baatsen; Pieter-Jan De Bock; Kris Gevaert; Pieter Vanden Berghe; Patrik Verstreken; Bart De Strooper; Diederik Moechars
Journal:  J Cell Sci       Date:  2015-02-01       Impact factor: 5.285

6.  Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

Authors:  Bruno Nervi; Pablo Ramirez; Michael P Rettig; Geoffrey L Uy; Matthew S Holt; Julie K Ritchey; Julie L Prior; David Piwnica-Worms; Gary Bridger; Timothy J Ley; John F DiPersio
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

Review 7.  CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches.

Authors:  Karin Williams; Karan Motiani; Premkumar Vummidi Giridhar; Susan Kasper
Journal:  Exp Biol Med (Maywood)       Date:  2013-03

8.  Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche.

Authors:  Fumio Arai; Atsushi Hirao; Masako Ohmura; Hidetaka Sato; Sahoko Matsuoka; Keiyo Takubo; Keisuke Ito; Gou Young Koh; Toshio Suda
Journal:  Cell       Date:  2004-07-23       Impact factor: 41.582

9.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1.

Authors:  Daniel J Ceradini; Anita R Kulkarni; Matthew J Callaghan; Oren M Tepper; Nicholas Bastidas; Mark E Kleinman; Jennifer M Capla; Robert D Galiano; Jamie P Levine; Geoffrey C Gurtner
Journal:  Nat Med       Date:  2004-07-04       Impact factor: 53.440

10.  Niche-based screening identifies small-molecule inhibitors of leukemia stem cells.

Authors:  Kimberly A Hartwell; Peter G Miller; Siddhartha Mukherjee; Alissa R Kahn; Alison L Stewart; David J Logan; Joseph M Negri; Mildred Duvet; Marcus Järås; Rishi Puram; Vlado Dancik; Fatima Al-Shahrour; Thomas Kindler; Zuzana Tothova; Shrikanta Chattopadhyay; Thomas Hasaka; Rajiv Narayan; Mingji Dai; Christina Huang; Sebastian Shterental; Lisa P Chu; J Erika Haydu; Jae Hung Shieh; David P Steensma; Benito Munoz; Joshua A Bittker; Alykhan F Shamji; Paul A Clemons; Nicola J Tolliday; Anne E Carpenter; D Gary Gilliland; Andrew M Stern; Malcolm A S Moore; David T Scadden; Stuart L Schreiber; Benjamin L Ebert; Todd R Golub
Journal:  Nat Chem Biol       Date:  2013-10-27       Impact factor: 15.040

View more
  36 in total

1.  CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.

Authors:  John N Allan; Gail J Roboz; Gulce Askin; Ellen Ritchie; Joseph Scandura; Paul Christos; Duane C Hassane; Monica L Guzman
Journal:  Leuk Lymphoma       Date:  2017-07-18

2.  Periarteriolar Glioblastoma Stem Cell Niches Express Bone Marrow Hematopoietic Stem Cell Niche Proteins.

Authors:  Vashendriya V V Hira; Jill R Wormer; Hala Kakar; Barbara Breznik; Britt van der Swaan; Renske Hulsbos; Wikky Tigchelaar; Zbynek Tonar; Mohammed Khurshed; Remco J Molenaar; Cornelis J F Van Noorden
Journal:  J Histochem Cytochem       Date:  2018-01-03       Impact factor: 2.479

3.  HIF-1α inhibition by 2-methoxyestradiol induces cell death via activation of the mitochondrial apoptotic pathway in acute myeloid leukemia.

Authors:  Nana Zhe; Shuya Chen; Zhen Zhou; Ping Liu; Xiaojing Lin; Meisheng Yu; Bingqing Cheng; Yaming Zhang; Jishi Wang
Journal:  Cancer Biol Ther       Date:  2016-04-15       Impact factor: 4.742

Review 4.  Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.

Authors:  Clara S Mundry; Kirsten C Eberle; Pankaj K Singh; Michael A Hollingsworth; Kamiya Mehla
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-06-21       Impact factor: 10.680

Review 5.  Predicting Chemotherapy Resistance in AML.

Authors:  Cecilia C S Yeung; Jerald Radich
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

6.  Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia.

Authors:  Sujan Piya; Steven M Kornblau; Vivian R Ruvolo; Hong Mu; Peter P Ruvolo; Teresa McQueen; R Eric Davis; Numsen Hail; Hagop Kantarjian; Michael Andreeff; Gautam Borthakur
Journal:  Blood       Date:  2016-06-07       Impact factor: 22.113

7.  Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival.

Authors:  Oscar Brück; Olli Dufva; Helena Hohtari; Sami Blom; Riku Turkki; Mette Ilander; Panu Kovanen; Celine Pallaud; Pedro Marques Ramos; Hanna Lähteenmäki; Katja Välimäki; Mohamed El Missiry; Antonio Ribeiro; Olli Kallioniemi; Kimmo Porkka; Teijo Pellinen; Satu Mustjoki
Journal:  Blood Adv       Date:  2020-01-28

8.  Alginate foam-based three-dimensional culture to investigate drug sensitivity in primary leukaemia cells.

Authors:  Mahroo Karimpoor; Eva Yebra-Fernandez; Maryam Parhizkar; Mine Orlu; Duncan Craig; Jamshid S Khorashad; Mohan Edirisinghe
Journal:  J R Soc Interface       Date:  2018-04       Impact factor: 4.118

9.  The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Authors:  Elizabeth C Townsend; Mark A Murakami; Alexandra Christodoulou; Amanda L Christie; Johannes Köster; Tiffany A DeSouza; Elizabeth A Morgan; Scott P Kallgren; Huiyun Liu; Shuo-Chieh Wu; Olivia Plana; Joan Montero; Kristen E Stevenson; Prakash Rao; Raga Vadhi; Michael Andreeff; Philippe Armand; Karen K Ballen; Patrizia Barzaghi-Rinaudo; Sarah Cahill; Rachael A Clark; Vesselina G Cooke; Matthew S Davids; Daniel J DeAngelo; David M Dorfman; Hilary Eaton; Benjamin L Ebert; Julia Etchin; Brant Firestone; David C Fisher; Arnold S Freedman; Ilene A Galinsky; Hui Gao; Jacqueline S Garcia; Francine Garnache-Ottou; Timothy A Graubert; Alejandro Gutierrez; Ensar Halilovic; Marian H Harris; Zachary T Herbert; Steven M Horwitz; Giorgio Inghirami; Andrew M Intlekofer; Moriko Ito; Shai Izraeli; Eric D Jacobsen; Caron A Jacobson; Sébastien Jeay; Irmela Jeremias; Michelle A Kelliher; Raphael Koch; Marina Konopleva; Nadja Kopp; Steven M Kornblau; Andrew L Kung; Thomas S Kupper; Nicole R LeBoeuf; Ann S LaCasce; Emma Lees; Loretta S Li; A Thomas Look; Masato Murakami; Markus Muschen; Donna Neuberg; Samuel Y Ng; Oreofe O Odejide; Stuart H Orkin; Rachel R Paquette; Andrew E Place; Justine E Roderick; Jeremy A Ryan; Stephen E Sallan; Brent Shoji; Lewis B Silverman; Robert J Soiffer; David P Steensma; Kimberly Stegmaier; Richard M Stone; Jerome Tamburini; Aaron R Thorner; Paul van Hummelen; Martha Wadleigh; Marion Wiesmann; Andrew P Weng; Jens U Wuerthner; David A Williams; Bruce M Wollison; Andrew A Lane; Anthony Letai; Monica M Bertagnolli; Jerome Ritz; Myles Brown; Henry Long; Jon C Aster; Margaret A Shipp; James D Griffin; David M Weinstock
Journal:  Cancer Cell       Date:  2016-04-11       Impact factor: 31.743

10.  CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.

Authors:  David K Edwards; Kevin Watanabe-Smith; Angela Rofelty; Alisa Damnernsawad; Ted Laderas; Adam Lamble; Evan F Lind; Andy Kaempf; Motomi Mori; Mara Rosenberg; Amanda d'Almeida; Nicola Long; Anupriya Agarwal; David Tyler Sweeney; Marc Loriaux; Shannon K McWeeney; Jeffrey W Tyner
Journal:  Blood       Date:  2018-11-13       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.